Anti-acid therapy in idiopathic pulmonary fibrosis: insights from the INPULSIS® trials

BACKGROUND: The benefits and risks of anti-acid medication in patients with idiopathic pulmonary fibrosis (IPF) remain a topic of debate. We investigated whether use of anti-acid medication at baseline was associated with differences in the natural course of disease or influenced the treatment effec...

Descripción completa

Detalles Bibliográficos
Autores principales: Costabel, Ulrich, Behr, Jürgen, Crestani, Bruno, Stansen, Wibke, Schlenker-Herceg, Rozsa, Stowasser, Susanne, Raghu, Ganesh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6122773/
https://www.ncbi.nlm.nih.gov/pubmed/30176872
http://dx.doi.org/10.1186/s12931-018-0866-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6122773/
https://www.ncbi.nlm.nih.gov/pubmed/30176872
http://dx.doi.org/10.1186/s12931-018-0866-0

Ejemplares similares